373 related articles for article (PubMed ID: 18154547)
1. beta-Lactams without a suicide inhibitor.
Giamarellou H
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
[TBL] [Abstract][Full Text] [Related]
2. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.
Balakrishnan I; Awad-El-Kariem FM; Aali A; Kumari P; Mulla R; Tan B; Brudney D; Ladenheim D; Ghazy A; Khan I; Virgincar N; Iyer S; Carryn S; Van de Velde S
J Antimicrob Chemother; 2011 Nov; 66(11):2628-31. PubMed ID: 21810837
[TBL] [Abstract][Full Text] [Related]
3. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
MacGowan A
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():166-8. PubMed ID: 18154541
[TBL] [Abstract][Full Text] [Related]
4. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
[TBL] [Abstract][Full Text] [Related]
5. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
Livermore DM; Hope R; Mushtaq S; Warner M
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex beta-lactamase patterns including extended-spectrum enzymes.
Segatore B; Setacci D; Perilli M; Franchino L; Franceschini N; Agnifili A; Rossolini GM; Amicosante G
Int J Antimicrob Agents; 2004 May; 23(5):480-6. PubMed ID: 15120727
[TBL] [Abstract][Full Text] [Related]
8. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC
Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
[TBL] [Abstract][Full Text] [Related]
9. Extended-spectrum beta-lactamases.
Turner PJ
Clin Infect Dis; 2005 Aug; 41 Suppl 4():S273-5. PubMed ID: 16032564
[TBL] [Abstract][Full Text] [Related]
10. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
Hombach M; Mouttet B; Bloemberg GV
J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
[TBL] [Abstract][Full Text] [Related]
11. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
Harada S; Ishii Y; Yamaguchi K
Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
[TBL] [Abstract][Full Text] [Related]
12. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Nguyen HM; Shier KL; Graber CJ
J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
[TBL] [Abstract][Full Text] [Related]
13. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide.
Drieux L; Brossier F; Sougakoff W; Jarlier V
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():90-103. PubMed ID: 18154532
[TBL] [Abstract][Full Text] [Related]
15. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of clinical strains resistant to various beta-lactams in a tertiary care hospital in India.
Datta P; Thakur A; Mishra B; Gupta V
Jpn J Infect Dis; 2004 Aug; 57(4):146-9. PubMed ID: 15329445
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases.
Sanders CC
J Chemother; 1996 Feb; 8 Suppl 2():57-62. PubMed ID: 8738847
[TBL] [Abstract][Full Text] [Related]
18. A simple disc diffusion method for detecting AmpC and extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae.
Derbyshire H; Kay G; Evans K; Vaughan C; Kavuri U; Winstanley T
J Antimicrob Chemother; 2009 Mar; 63(3):497-501. PubMed ID: 19155228
[TBL] [Abstract][Full Text] [Related]
19. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
Kahlmeter G
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Korean hospitals.
Ko KS; Lee MY; Song JH; Lee H; Jung DS; Jung SI; Kim SW; Chang HH; Yeom JS; Kim YS; Ki HK; Chung DR; Kwon KT; Peck KR; Lee NY
Diagn Microbiol Infect Dis; 2008 Aug; 61(4):453-9. PubMed ID: 18482815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
